Gilead Sciences Inc. (GILD)
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $135.87, denoting a -1.29% move from the preceding trading day.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today
In the most recent trading session, Gilead Sciences (GILD) closed at $140.45, indicating a +1.02% shift from the previous trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic acquisitions beyond HIV.
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts
Gilead Sciences (GILD) reached $141.54 at the closing of the latest trading day, reflecting a +1.97% change compared to its last close.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion
Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in contingency payments.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline.
Gilead to acquire Tubulis GmbH for up to $5 billion
Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, boosting the U.S. drugmaker's pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
